Loading...

NUVL NUVALENT INC Product Launches 8-K Filing

NVLN

NVL

NUVALENT INC

(NUVL)

2025 8-K

Financial Results Update

New Drug Application

Financial Results Update

Financial Estimate Release

Royalty Acquisition

Stock Offering Announcement

Positive Data Report

Financial Results Update

New Drug Filing

Financial Statements

Clinical Trials

Product Expansion

Financial Statements

Board Resignation

Financial Results

Corporate Updates

New Director Elected

Financial Results

Clinical Trial Update

Financial Results Announcement

Clinical Trial Initiation

Annual Meeting Voting Results

FDA Breakthrough Therapy De...

Financial Results Announcement

Financial Results Announcement

Financial Condition

Financial Results Announcement

Underwriting Agreement

Clinical Data Update

Clinical Data Announcement

Financial Results Announcement

Annual Meeting and Amendmen...

Financial Results Announcement

Financial Results Announcement

Monitoring SVB's receivership

External Links:

On September 22, 2025, Nuvalent, Inc. submitted a New Drug Application to the U.S. FDA for zidesamtinib, targeting advanced ROS1-positive non-small cell lung cancer in patients pre-treated with tyrosine kinase inhibitors.

AI Assistant

NUVALENT INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.